Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Mg 0103
2. Mg 4230
3. Mg 4915
4. Mg 5026
5. Mg-0103
6. Mg-4230
7. Mg-4915
8. Mg-5026
9. Mg0103
10. Mg4230
11. Mg4915
12. Mg5206
13. Mgcd 0103
14. Mgcd-0103
15. Mgcd0103
16. N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
1. 726169-73-9
2. Mgcd0103
3. Mgcd-0103
4. Mgcd 0103
5. N-(2-aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide
6. N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide
7. Mocetinostat (mgcd0103)
8. 9003-99-0
9. Mg0103
10. Mocetinostat (mgcd-0103)
11. Mg 0103
12. Mocetinostat (mgcd0103, Mg0103)
13. A6gwb8t96j
14. Chembl272980
15. Mg-0103
16. N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
17. 726169-73-9 (free Base)
18. Mocetinostat (usan/inn)
19. N-(2-aminophenyl)-4-(((4-(pyridin-3-yl)pyrimidin-2-yl)amino)methyl)benzamide
20. N-(2-aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide
21. N-(2-aminophenyl)-4-[[[4-(3-pyridyl)pyrimidin-2-yl]amino]methyl]benzamide
22. N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide
23. Benzamide, N-(2-aminophenyl)-4-(((4-(3-pyridinyl)-2-pyrimidinyl)amino)methyl)-
24. Mocetinostat [usan]
25. Mocetinostat [usan:inn]
26. Unii-a6gwb8t96j
27. Mgcd0103 (mocetinostat)
28. Horseradish Peroxidase
29. Myeloperoxidase (usan)
30. Mgcd010,3mocetinostat
31. Mocetinostat [inn]
32. Mgcd0103 - Mocetinostat
33. Mls006010181
34. Mocetinostat [who-dd]
35. Schembl157027
36. Gtpl7008
37. Bdbm24624
38. Chebi:94525
39. Dtxsid80222945
40. Ex-a049
41. Bcpp000163
42. Hms3426i07
43. Hms3654k06
44. Bcp01814
45. Bbl102287
46. Mfcd10565970
47. Nsc760143
48. S1122
49. Stl556086
50. Zinc13986811
51. Akos016340325
52. Bcp9000925
53. Bd-0114
54. Ccg-208763
55. Cs-0502
56. Db11830
57. Nsc-760143
58. Sb16666
59. Ncgc00263182-01
60. Ncgc00263182-02
61. Ncgc00263182-11
62. Ac-30281
63. Hy-12164
64. Smr004701289
65. Ft-0627651
66. Ft-0741876
67. Sw218130-2
68. Ec-000.2284
69. D09641
70. D09643
71. 169m739
72. Au-004/43508107
73. Q424869
74. J-522866
75. Brd-k16485616-001-01-4
76. Brd-k16485616-001-04-8
77. N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide
78. N-(2-aminophenyl)-4-({[4-(3-pyridinyl)-2-pyrimidinyl]amino}methyl)benzamide
79. N-(2-aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide;mgcd0103;mocetinostat;mgcd0103(mocetinostat)
| Molecular Weight | 396.4 g/mol |
|---|---|
| Molecular Formula | C23H20N6O |
| XLogP3 | 2.8 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 396.16985928 g/mol |
| Monoisotopic Mass | 396.16985928 g/mol |
| Topological Polar Surface Area | 106 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 538 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
All HDAC inhibitors induce histone H3 hyperacetylation, correlating with inhibition of proliferation, induction of cell differentiation and apoptosis.
Histone Deacetylase Inhibitors
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains. (See all compounds classified as Histone Deacetylase Inhibitors.)
Mocetinostat is a novel isotypic-selective inhibitor of the enzyme histone deacetylase (HDAC). HDAC inhibitors act by turning on tumour suppressor genes that have been inappropriately turned off. Tumour suppressor genes are a natural defense against cancer. It is therefore hypothesized that specifically inhibiting those HDACs involved in cancer with Mocetinostat may restore normal cell function and reduce or inhibit tumour growth.
Digital Content 
NEWS #PharmaBuzz
ABOUT THIS PAGE
71
PharmaCompass offers a list of Mocetinostat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Mocetinostat manufacturer or Mocetinostat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Mocetinostat manufacturer or Mocetinostat supplier.
PharmaCompass also assists you with knowing the Mocetinostat API Price utilized in the formulation of products. Mocetinostat API Price is not always fixed or binding as the Mocetinostat Price is obtained through a variety of data sources. The Mocetinostat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Mocetinostat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mocetinostat, including repackagers and relabelers. The FDA regulates Mocetinostat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mocetinostat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Mocetinostat supplier is an individual or a company that provides Mocetinostat active pharmaceutical ingredient (API) or Mocetinostat finished formulations upon request. The Mocetinostat suppliers may include Mocetinostat API manufacturers, exporters, distributors and traders.
Mocetinostat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mocetinostat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mocetinostat GMP manufacturer or Mocetinostat GMP API supplier for your needs.
A Mocetinostat CoA (Certificate of Analysis) is a formal document that attests to Mocetinostat's compliance with Mocetinostat specifications and serves as a tool for batch-level quality control.
Mocetinostat CoA mostly includes findings from lab analyses of a specific batch. For each Mocetinostat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mocetinostat may be tested according to a variety of international standards, such as European Pharmacopoeia (Mocetinostat EP), Mocetinostat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mocetinostat USP).
